MedRx Co., Ltd (TSE: 4586)
Health Care · Pharmaceuticals · JP
¥66.00
+1.54% today · -42.6% 1Y
MedRx Co., Ltd (TSE: 4586) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $24.65M and employs 21 people.
Over the last twelve months the share price has lost 42.6%, trading between 48.00 and 225.00.
Tweenvest scores MedRx Co., Ltd across four factors: quality 28/100, value 71/100. Its strongest factor is value.
4586 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $24.65M
- Revenue (TTM)
- $744.41K
- P/E
- —
- EPS
- -14.58
- Dividend yield
- —
- Beta (5Y)
- 0.57
- 52-week high
- ¥225.00
- 52-week low
- ¥48.00
- Avg volume (3M)
- —
- Shares outstanding
- 59.37M
- Employees
- 21
- Next earnings
- —
About MedRx Co., Ltd
Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.
- ISIN
- JP3921220004
- Founded
- 2002
- Listed since
- Feb 14, 2013
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.80 | +0.11% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.72 | +0.51% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.